Shenglan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shenglan Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Wenbin Li
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
3 shared publications - Can Wang
Beijing Tiantan Hospital, Capital Medical University, China
2 shared publications - Feng Chen
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications - Jiachen Wang
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications - Mengqian Huang
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications - Yuxiao Chen
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 14 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Causal effect between circulating metabolic markers and glioma: a bidirectional, two-sample, Bayesian weighted Mendelian randomization
Glioma is the most common malignant tumor in the central nervous system with significant challenges for its treatment and prognosis. Based on publicly available genome-wide association study data, this study employed a bidirectional, two-sample Mendelian randomization (MR) analysis, combined with Bayesian weighted MR, to investigate the causal effect of 233 circulating metabolic traits on glioma and its subtypes, with the expectation of discovering new diagnostic and therapeutic targets. The MR study revealed that the Total cholesterol to total lipids ratio in large VLDL and the Ratio of polyunsaturated fatty acids to total fatty acids (PUFAbyFA) are risk factors for glioma, while free cholesterol or phospholipids in small HDL are protective against glioma. The free cholesterol to total lipids ratio in IDL, the ratios of total cholesterol or cholesteryl esters to total lipids in small or medium VLDL, as well as linoleic acid (LA 18:2), phosphatidylcholine, and sphingomyelins levels are risk factors for non-GBM glioma. Free cholesterol in small HDL is identified as a protective factor for non-GBM glioma. The results were robust to sensitivity analyses and Bayesian weighted mendelian randomization. The causal effects of glioma on circulating metabolites were explored through reverse mendelian randomization. The results provide potential biomarkers for the early diagnosis and treatment of glioma.
- 14 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Open AccessCausal effect between circulating metabolic markers and glioma: a bidirectional, two-sample, Bayesian weighted Mendelian randomization
Glioma is the most common malignant tumor in the central nervous system with significant challenges for its treatment and prognosis. Based on publicly available genome-wide association study data, this study employed a bidirectional, two-sample Mendelian randomization (MR) analysis, combined with Bayesian weighted MR, to investigate the causal effect of 233 circulating metabolic traits on glioma and its subtypes, with the expectation of discovering new diagnostic and therapeutic targets. The MR study revealed that the Total cholesterol to total lipids ratio in large VLDL and the Ratio of polyunsaturated fatty acids to total fatty acids (PUFAbyFA) are risk factors for glioma, while free cholesterol or phospholipids in small HDL are protective against glioma. The free cholesterol to total lipids ratio in IDL, the ratios of total cholesterol or cholesteryl esters to total lipids in small or medium VLDL, as well as linoleic acid (LA 18:2), phosphatidylcholine, and sphingomyelins levels are risk factors for non-GBM glioma. Free cholesterol in small HDL is identified as a protective factor for non-GBM glioma. The results were robust to sensitivity analyses and Bayesian weighted mendelian randomization. The causal effects of glioma on circulating metabolites were explored through reverse mendelian randomization. The results provide potential biomarkers for the early diagnosis and treatment of glioma.
- Open Access
- 6 August 2024
- Published by MDPI AG in Preprints.org
ScRNA-seq Unveils the Functional Characteristics of Glioma-Associated Macrophages and the Regulatory Effects of Chlorogenic Acid on the Immune Microenvironment—A Study Based on Mouse Models and Clinical Practice
Glioma is the most common primary malignant brain tumors. Despite advances in surgical techniques and treatment regimens, the therapeutic effects remain unsatisfactory. Immunotherapy has brought new hope to glioma patients, but the immunosuppressive nature of the tumor microenvironment (TME) has limited the therapeutic outcomes. This study aims to reveal the subpopulations and functional characteristics of tumor-associated macrophages (TAMs), to explore the regulatory effects of chlorogenic acid on the immune microenvironment, and investigate its potential for clinical application. In this study, Chlorogenic acid slowed tumor growth in the mouse model and extended the survival time of the mice. ScRNA-seq analysis elucidated the differentiation trajectories and functional characteristics of BMDMs and microglia, revealing the regulatory effects of chlorogenic acid on these two populations. It enhanced the antigen-presenting function of macrophages and the gene expression related to T-cell immune activation, activated microglia through the JAK-STAT pathway, and improved antitumor functions. Using the target prediction database, a PPI and molecular docking model were constructed, confirming the good affinity of chlorogenic acid with STAT1. A case of a patient treated with chlorogenic acid was reviewed, who survived for 5 years and 6 months, achieved partial remission (PR) after 9 months of treatment, and remains alive with no new symptoms or toxic side effects. Our study revealed the subtypes and differentiation trajectories of tumor-associated macrophages. Chlorogenic acid significantly improved the immune microenvironment of glioma by modulating the function of bone marrow-derived mono-macrophages (BMDMs) and microglia, demonstrating good antitumor effects. This study provides new insights for targeting the regulation of the TME and offers theoretical and practical support for the clinical application of chlorogenic acid.
- 6 August 2024
- Published by MDPI AG in Preprints.org
Open AccessScRNA-seq Unveils the Functional Characteristics of Glioma-Associated Macrophages and the Regulatory Effects of Chlorogenic Acid on the Immune Microenvironment—A Study Based on Mouse Models and Clinical Practice
Glioma is the most common primary malignant brain tumors. Despite advances in surgical techniques and treatment regimens, the therapeutic effects remain unsatisfactory. Immunotherapy has brought new hope to glioma patients, but the immunosuppressive nature of the tumor microenvironment (TME) has limited the therapeutic outcomes. This study aims to reveal the subpopulations and functional characteristics of tumor-associated macrophages (TAMs), to explore the regulatory effects of chlorogenic acid on the immune microenvironment, and investigate its potential for clinical application. In this study, Chlorogenic acid slowed tumor growth in the mouse model and extended the survival time of the mice. ScRNA-seq analysis elucidated the differentiation trajectories and functional characteristics of BMDMs and microglia, revealing the regulatory effects of chlorogenic acid on these two populations. It enhanced the antigen-presenting function of macrophages and the gene expression related to T-cell immune activation, activated microglia through the JAK-STAT pathway, and improved antitumor functions. Using the target prediction database, a PPI and molecular docking model were constructed, confirming the good affinity of chlorogenic acid with STAT1. A case of a patient treated with chlorogenic acid was reviewed, who survived for 5 years and 6 months, achieved partial remission (PR) after 9 months of treatment, and remains alive with no new symptoms or toxic side effects. Our study revealed the subtypes and differentiation trajectories of tumor-associated macrophages. Chlorogenic acid significantly improved the immune microenvironment of glioma by modulating the function of bone marrow-derived mono-macrophages (BMDMs) and microglia, demonstrating good antitumor effects. This study provides new insights for targeting the regulation of the TME and offers theoretical and practical support for the clinical application of chlorogenic acid.
- RetractedOpen Access
- 1 September 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 141, 111793
RETRACTED: Liposomal honokiol promotes hair growth via activating Wnt3a/β-catenin signaling pathway and down regulating TGF-β1 in C57BL/6N mice
- 1 September 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 141, 111793
RetractedOpen AccessRETRACTED: Liposomal honokiol promotes hair growth via activating Wnt3a/β-catenin signaling pathway and down regulating TGF-β1 in C57BL/6N mice